Skip to main content

and
  1. Article

    Open Access

    The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

    Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2. The protein tyrosine phosphatases...

    Christina K. Baumgartner, Hakimeh Ebrahimi-Nik, Arvin Iracheta-Vellve in Nature (2023)

  2. No Access

    Article

    Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

    Most patients with cancer either do not respond to immune checkpoint blockade or develop resistance to it, often because of acquired mutations that impair antigen presentation. Here we show that loss of functi...

    Jeffrey J. Ishizuka, Robert T. Manguso, Collins K. Cheruiyot, Kevin Bi in Nature (2019)